LDLRAD4

Summary

LDLRAD4 (low density lipoprotein receptor class A domain containing 4, HGNC:1224) is a protein-coding gene on chromosome 18p11.21, encoding Low-density lipoprotein receptor class A domain-containing protein 4 (O15165). Functions as a negative regulator of TGF-beta signaling and thereby probably plays a role in cell proliferation, differentiation, apoptosis, motility, extracellular matrix production and immunosuppression.

Enables R-SMAD binding activity. Involved in negative regulation of cell migration; negative regulation of epithelial to mesenchymal transition; and negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway. Located in early endosome membrane.

Source: NCBI Gene 753 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 61 total
• MANE Select transcript: NM_001378100

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1224
Approved symbol	LDLRAD4
Name	low density lipoprotein receptor class A domain containing 4
Location	18p11.21
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000168675
Ensembl biotype	protein_coding
OMIM	606571
Entrez	753

Gene structure

Transcript identifiers

Ensembl transcripts: 61 — 40 protein_coding, 15 protein_coding_CDS_not_defined, 3 retained_intron, 3 nonsense_mediated_decay

ENST00000359446, ENST00000361303, ENST00000399848, ENST00000435606, ENST00000585931, ENST00000586207, ENST00000586222, ENST00000586765, ENST00000587344, ENST00000587440, ENST00000587600, ENST00000587757, ENST00000587905, ENST00000590115, ENST00000590308, ENST00000590371, ENST00000592657, ENST00000592812, ENST00000592991, ENST00000593236, ENST00000610087, ENST00000676672, ENST00000676773, ENST00000676815, ENST00000676891, ENST00000677055, ENST00000677304, ENST00000677387, ENST00000677744, ENST00000677867, ENST00000677910, ENST00000678223, ENST00000678309, ENST00000678400, ENST00000678459, ENST00000678556, ENST00000679091, ENST00000679167, ENST00000679177, ENST00000679303, ENST00000896326, ENST00000896327, ENST00000896328, ENST00000896329, ENST00000896330, ENST00000896331, ENST00000896332, ENST00000896333, ENST00000896334, ENST00000896335, ENST00000896336, ENST00000896337, ENST00000896338, ENST00000896339, ENST00000896340, ENST00000943635, ENST00000943636, ENST00000943637, ENST00000943638, ENST00000943639, ENST00000943640

RefSeq mRNA: 16 — MANE Select: NM_001378100 NM_001003674, NM_001003675, NM_001276249, NM_001276251, NM_001378098, NM_001378099, NM_001378100, NM_001378101, NM_001394662, NM_001394663, NM_001394664, NM_001394665, NM_001394666, NM_001394667, NM_181481, NM_181482

CCDS: CCDS32793, CCDS32794, CCDS32795, CCDS42415, CCDS62392, CCDS92439

Canonical transcript exons

ENST00000359446 — 7 exons

Exon	Start	End
ENSE00001269476	13438244	13438384
ENSE00001354297	13387341	13387762
ENSE00001406954	13278105	13278188
ENSE00002821696	13218760	13218988
ENSE00003509727	13643359	13643412
ENSE00003553777	13621117	13621271
ENSE00003584051	13645127	13652751

Expression profiles

Bgee: expression breadth ubiquitous, 272 present calls, max score 97.09.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.9159 / max 594.0381, expressed in 1064 samples.

FANTOM5 promoters (40 alternative TSS)

Promoter ID	TPM avg	Samples expressed
169576	4.0260	289
169526	2.2763	669
169555	1.6841	395
169548	1.0237	177
169530	0.9266	304
169556	0.7451	298
169570	0.7068	245
169568	0.5946	171
169529	0.5286	197
169575	0.4900	178

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	97.09	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.24	gold quality
calcaneal tendon	UBERON:0003701	93.67	gold quality
spinal cord	UBERON:0002240	93.18	gold quality
colonic epithelium	UBERON:0000397	92.62	gold quality
putamen	UBERON:0001874	92.45	gold quality
choroid plexus epithelium	UBERON:0003911	91.93	gold quality
primary visual cortex	UBERON:0002436	91.62	gold quality
caudate nucleus	UBERON:0001873	91.42	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.62	gold quality
sural nerve	UBERON:0015488	90.54	gold quality
tendon	UBERON:0000043	90.38	gold quality
corpus callosum	UBERON:0002336	90.37	gold quality
substantia nigra	UBERON:0002038	89.66	gold quality
tibia	UBERON:0000979	89.61	gold quality
right atrium auricular region	UBERON:0006631	89.61	gold quality
Brodmann (1909) area 10	UBERON:0013541	88.80	gold quality
prostate gland	UBERON:0002367	88.61	gold quality
blood vessel layer	UBERON:0004797	88.47	gold quality
midbrain	UBERON:0001891	88.34	gold quality
body of uterus	UBERON:0009853	88.31	gold quality
occipital lobe	UBERON:0002021	88.11	gold quality
prefrontal cortex	UBERON:0000451	88.05	gold quality
descending thoracic aorta	UBERON:0002345	88.00	gold quality
ganglionic eminence	UBERON:0004023	87.47	gold quality
thoracic aorta	UBERON:0001515	87.37	gold quality
ascending aorta	UBERON:0001496	87.33	gold quality
nucleus accumbens	UBERON:0001882	87.10	gold quality
amygdala	UBERON:0001876	86.90	gold quality
thymus	UBERON:0002370	86.88	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-HCAD-30	yes	1618.13
E-HCAD-4	yes	56.77
E-HCAD-35	yes	42.24
E-CURD-119	yes	31.71
E-HCAD-25	yes	18.17
E-CURD-122	yes	15.58
E-CURD-46	yes	11.67
E-ANND-3	yes	6.88
E-ANND-2	no	975.08

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

197 targeting LDLRAD4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-548J-3P	99.94	72.61	4881

Literature-anchored findings (GeneRIF, showing 3)

• Data suggest that C18ORF1 acts as a gatekeeper that abrogates excessive TGF-beta signaling. (PMID:24627487)
• Depletion of LDLRAD4 in HepG2 liver cancer cells inhibited tumorigenesis in nude mice. These results reveal an oncogenic role of LDLRAD4 in tumorigenesis through its association with Nedd4. (PMID:28888937)
• Identification of low-density lipoprotein receptor class A domain containing 4 (LDLRAD4) as a prognostic indicator in primary gastrointestinal stromal tumors. (PMID:32507364)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ldlrad4b	ENSDARG00000054941
danio_rerio	ldlrad4a	ENSDARG00000070555
mus_musculus	Ldlrad4	ENSMUSG00000024544
rattus_norvegicus	Ldlrad4	ENSRNOG00000016879
drosophila_melanogaster	CG5151	FBGN0036576

Paralogs (1): PMEPA1 (ENSG00000124225)

Protein

Protein identifiers

Low-density lipoprotein receptor class A domain-containing protein 4 — O15165 (reviewed: O15165)

All UniProt accessions (10): O15165, A0A7I2V2E6, A0A7I2V2Z9, A0A7I2V3Q9, A0A7I2V3W1, A0A7I2V3Z2, A0A7I2V575, A0A7I2YQI3, K7EJM9, K7EMG1

UniProt curated annotations — full annotation on UniProt →

Function. Functions as a negative regulator of TGF-beta signaling and thereby probably plays a role in cell proliferation, differentiation, apoptosis, motility, extracellular matrix production and immunosuppression. In the canonical TGF-beta pathway, ZFYVE9/SARA recruits the intracellular signal transducer and transcriptional modulators SMAD2 and SMAD3 to the TGF-beta receptor. Phosphorylated by the receptor, SMAD2 and SMAD3 then form a heteromeric complex with SMAD4 that translocates to the nucleus to regulate transcription. Through interaction with SMAD2 and SMAD3, LDLRAD4 may compete with ZFYVE9 and SMAD4 and prevent propagation of the intracellular signal.

Subunit / interactions. Interacts with PMEPA1. Interacts (via the SMAD interaction motif) with SMAD2 and SMAD3.

Subcellular location. Early endosome membrane.

Tissue specificity. Expressed in lymphocytes.

Domain organisation. The SMAD interaction motif is required for interaction with SMAD2 and SMAD3 and the negative regulation of TGF-beta signaling.

Similarity. Belongs to the PMEPA1 family.

Isoforms (8)

UniProt ID	Names	Canonical?
O15165-1	Alpha-1	yes
O15165-2	Alpha-2
O15165-3	Beta-1
O15165-4	Beta-2
O15165-5	5
O15165-6	6
O15165-7	7
O15165-8	8

RefSeq proteins (15): NP_001003674, NP_001003675, NP_001263178, NP_001365027, NP_001365028, NP_001365029, NP_001365030, NP_001381591, NP_001381592, NP_001381593, NP_001381594, NP_001381595, NP_001381596, NP_852146, NP_852147 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002172	LDrepeatLR_classA_rpt	Repeat
IPR023415	LDLR_class-A_CS	Conserved_site
IPR036055	LDL_receptor-like_sf	Homologous_superfamily
IPR043445	TMEPAI/LRAD4	Family

Pfam: PF00057

UniProt features (20 total): splice variant 5, sequence conflict 3, short sequence motif 3, topological domain 2, disulfide bond 2, chain 1, transmembrane region 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O15165-F1	58.44	0.06

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 19–38, 32–47

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 270 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GOBP_SMAD_PROTEIN_SIGNAL_TRANSDUCTION, VERHAAK_AML_WITH_NPM1_MUTATED_DN, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, WANG_CLIM2_TARGETS_UP, TATTATA_MIR374, GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_TO_MESENCHYMAL_TRANSITION, CAGCTG_AP4_Q5, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_DN, MAHAJAN_RESPONSE_TO_IL1A_DN, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, ONKEN_UVEAL_MELANOMA_UP, GOBP_MESENCHYMAL_CELL_DIFFERENTIATION, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5

GO Biological Process (5): negative regulation of epithelial to mesenchymal transition (GO:0010719), negative regulation of cell migration (GO:0030336), negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512), negative regulation of SMAD protein signal transduction (GO:0060392), negative regulation of signal transduction (GO:0009968)

GO Molecular Function (2): R-SMAD binding (GO:0070412), protein binding (GO:0005515)

GO Cellular Component (4): Golgi membrane (GO:0000139), membrane (GO:0016020), early endosome membrane (GO:0031901), endosome (GO:0005768)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	2
epithelial to mesenchymal transition	1
regulation of epithelial to mesenchymal transition	1
negative regulation of cell differentiation	1
negative regulation of multicellular organismal process	1
cell migration	1
regulation of cell migration	1
negative regulation of cell motility	1
transforming growth factor beta receptor signaling pathway	1
regulation of transforming growth factor beta receptor signaling pathway	1
regulation of SMAD protein signal transduction	1
SMAD protein signal transduction	1
negative regulation of intracellular signal transduction	1
signal transduction	1
regulation of signal transduction	1
negative regulation of cell communication	1
negative regulation of signaling	1
negative regulation of response to stimulus	1
SMAD binding	1
binding	1
Golgi apparatus	1
bounding membrane of organelle	1
cellular anatomical structure	1
early endosome	1
endosome membrane	1
endomembrane system	1
cytoplasmic vesicle	1

Protein interactions and networks

STRING

1848 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LDLRAD4	TSC22D1	Q15714	720
LDLRAD4	TPT1	P13693	535
LDLRAD4	AR	P10275	525
LDLRAD4	TSC22D3	Q99576	366
LDLRAD4	MC5R	P33032	333
LDLRAD4	ISM1	B1AKI9	324
LDLRAD4	ARMC12	Q5T9G4	306
LDLRAD4	TMEM158	Q8WZ71	304
LDLRAD4	MIMS1	Q96ND0	303
LDLRAD4	KANK4	Q5T7N3	302
LDLRAD4	ZFYVE9	O95405	300
LDLRAD4	CCDC144A	A2RUR9	287
LDLRAD4	HEPACAM	Q14CZ8	277
LDLRAD4	LMNTD2	Q8IXW0	270
LDLRAD4	MC2R	Q01718	268

IntAct

8 interactions, top by confidence:

A	B	Type	Score
NEDD4	LDLRAD4	psi-mi:“MI:0407”(direct interaction)	0.690
LDLRAD4	NEDD4	psi-mi:“MI:0914”(association)	0.690
LDLRAD4	WWP2	psi-mi:“MI:0914”(association)	0.530
TFAP2C	LDLRAD4	psi-mi:“MI:0915”(physical association)	0.370
KATNA1	LDLRAD4	psi-mi:“MI:0914”(association)	0.350

BioGRID (131): RTFDC1 (Affinity Capture-MS), HECW2 (Affinity Capture-MS), HECW1 (Affinity Capture-MS), WWP2 (Affinity Capture-MS), NEDD4 (Affinity Capture-MS), ITCH (Affinity Capture-MS), NEDD4L (Affinity Capture-MS), WWP1 (Affinity Capture-MS), TAX1BP1 (Affinity Capture-MS), WWC2 (Affinity Capture-MS), KIDINS220 (Affinity Capture-MS), NCAPD3 (Affinity Capture-MS), UBR3 (Affinity Capture-MS), ARFGEF2 (Affinity Capture-MS), UBR1 (Affinity Capture-MS)

ESM2 similar proteins: A2AR95, A4IHY6, B7ZWI3, D3ZF92, O15165, O43278, O75509, O88204, P98153, P98154, Q0VBF2, Q1L8G6, Q29RU0, Q4KMG9, Q566M8, Q5DTZ6, Q5HZW5, Q5R662, Q5R8E0, Q5RD34, Q5RF74, Q5VUB5, Q61003, Q68FU0, Q6AXS2, Q6NRX0, Q6UWW9, Q6ZPS6, Q6ZUJ8, Q7TQH7, Q86YD5, Q8BGN6, Q8BLD6, Q8BUJ9, Q8R182, Q8TEB7, Q8WUU8, Q91ZV2, Q91ZV3, Q96PD2

Diamond homologs: D2KUZ7, O15165, Q8BWJ4, Q969W9, Q9D7R2, E9Q6D8, P13671, P61134, P61135, Q29RU4, Q811M5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	49
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

6078 predictions. Top by Δscore:

Variant	Effect	Δscore
18:13438292:T:A	acceptor_gain	1.0000
18:13438381:AACT:A	donor_gain	1.0000
18:13438382:ACT:A	donor_gain	1.0000
18:13438383:CT:C	donor_gain	1.0000
18:13438383:CTGTA:C	donor_loss	1.0000
18:13438384:TGTAA:T	donor_loss	1.0000
18:13438385:G:GA	donor_loss	1.0000
18:13438385:G:GG	donor_gain	1.0000
18:13438386:TA:T	donor_loss	1.0000
18:13438387:AA:A	donor_loss	1.0000
18:13621110:A:AG	acceptor_gain	1.0000
18:13621110:AT:A	acceptor_gain	1.0000
18:13621111:T:A	acceptor_gain	1.0000
18:13621111:T:G	acceptor_gain	1.0000
18:13621112:G:A	acceptor_gain	1.0000
18:13621112:GGCA:G	acceptor_loss	1.0000
18:13621113:GCAG:G	acceptor_loss	1.0000
18:13621114:CAGC:C	acceptor_loss	1.0000
18:13621115:A:AG	acceptor_gain	1.0000
18:13621115:AGC:A	acceptor_gain	1.0000
18:13621115:AGCG:A	acceptor_gain	1.0000
18:13621116:G:GA	acceptor_gain	1.0000
18:13621116:GC:G	acceptor_gain	1.0000
18:13621116:GCG:G	acceptor_gain	1.0000
18:13621116:GCGG:G	acceptor_gain	1.0000
18:13621116:GCGGA:G	acceptor_gain	1.0000
18:13621268:GCAG:G	donor_gain	1.0000
18:13621270:AGGT:A	donor_loss	1.0000
18:13621272:G:GG	donor_gain	1.0000
18:13621272:GTG:G	donor_loss	1.0000

AlphaMissense

2038 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:13438297:T:A	C32S	0.999
18:13438298:G:C	C32S	0.999
18:13438315:T:A	C38S	0.999
18:13438316:G:A	C38Y	0.999
18:13438316:G:C	C38S	0.999
18:13645251:T:A	I172N	0.999
18:13645366:C:A	N210K	0.999
18:13645366:C:G	N210K	0.999
18:13438259:G:A	C19Y	0.998
18:13438260:C:G	C19W	0.998
18:13438297:T:C	C32R	0.998
18:13438298:G:A	C32Y	0.998
18:13438315:T:C	C38R	0.998
18:13438317:T:G	C38W	0.998
18:13645251:T:C	I172T	0.998
18:13645251:T:G	I172S	0.998
18:13645335:T:C	L200P	0.998
18:13645359:C:A	P208Q	0.998
18:13645368:G:C	R211P	0.998
18:13438252:T:C	F17L	0.997
18:13438254:C:A	F17L	0.997
18:13438254:C:G	F17L	0.997
18:13438258:T:A	C19S	0.997
18:13438258:T:C	C19R	0.997
18:13438259:G:C	C19S	0.997
18:13438299:T:G	C32W	0.997
18:13438316:G:T	C38F	0.997
18:13438330:G:C	D43H	0.997
18:13438330:G:T	D43Y	0.997
18:13438344:T:G	C47W	0.997

dbSNP variants (sampled 300 via entrez): RS1000015134 (18:13582372 G>A,T), RS1000025389 (18:13241094 A>G), RS1000029530 (18:13423911 G>A), RS1000038400 (18:13481640 G>A), RS1000049350 (18:13541228 A>G), RS1000049929 (18:13503988 A>G), RS1000051040 (18:13619618 G>A), RS1000056073 (18:13624511 T>A), RS1000056407 (18:13326926 A>G), RS1000059264 (18:13406207 C>G,T), RS1000064020 (18:13273269 G>A), RS1000065067 (18:13554544 C>G,T), RS1000067122 (18:13319307 T>G), RS1000074955 (18:13437387 A>G), RS1000076650 (18:13400219 A>G)

Disease associations

OMIM: gene MIM:606571 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST001749_1	Pancreatic cancer	6.000000e-07
GCST003059_20	Parkinson’s disease	1.000000e-06
GCST003854_35	Gut microbiota (functional units)	3.000000e-08
GCST004485_60	Survival in pancreatic cancer	2.000000e-07
GCST006444_11	Bone mineral density (hip)	3.000000e-06
GCST006976_137	Macular thickness	4.000000e-08
GCST007666_3	Depressive symptom improvement	7.000000e-07
GCST009028_18	Adverse response to drug	9.000000e-09
GCST009028_58	Adverse response to drug	2.000000e-08
GCST012490_571	Femur bone mineral density x serum urate levels interaction	3.000000e-11
GCST90002400_238	Plateletcrit	4.000000e-10
GCST90011900_154	Serum alkaline phosphatase levels	1.000000e-08

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0007874	gut microbiome measurement
EFO:0000638	overall survival
EFO:0007702	hip bone mineral density
EFO:0007006	depressive symptom measurement
EFO:0009658	adverse effect
EFO:0004531	urate measurement
EFO:0007985	platelet crit
EFO:0004533	alkaline phosphatase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects expression, affects methylation, decreases expression, increases methylation	7
Valproic Acid	affects expression, decreases expression, increases expression	5
Tetrachlorodibenzodioxin	affects cotreatment, increases expression, decreases expression	3
Aflatoxin B1	affects expression, affects methylation, decreases methylation	3
Estradiol	affects cotreatment, increases expression, decreases expression	2
Selenium	decreases reaction, increases expression	2
Tamoxifen	affects expression, affects cotreatment, increases expression	2
Cyclosporine	decreases expression, increases methylation	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
sotorasib	increases expression, affects cotreatment	1
biochanin A	decreases expression	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
sodium arsenite	affects methylation	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	affects methylation	1
pentanal	increases expression	1
abrine	decreases expression	1
licochalcone B	increases expression	1
trametinib	affects cotreatment, increases expression	1
NVP-BKM120	affects cotreatment, increases expression	1
Rosiglitazone	increases expression	1
Sunitinib	decreases expression	1
Leflunomide	increases expression	1
Acetaminophen	decreases expression	1
Amphotericin B	increases expression	1
Cadmium	increases expression, decreases reaction	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.